US 5,965,526 A · Pentapeptide with specific conformation, its production and use

Abstract

Cyclic pentapeptides are disclosed having the following formula (I) --Cyclo(-A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -A.sub.5 -)-- wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4 and A.sub.5, are amino acid residues. The pentapeptide has amino acid residues in positions 1-2-3 to form a .gamma.-turn, and amino acid residues in positions 3-4-5-1 to form a .beta.-turn in combination with the .gamma.-turn. D-.alpha.-amino acid residues are selected for A.sub.1, A.sub.3, and A.sub.5 and L-.alpha.-amino acid residues are selected for A.sub.2 and A.sub.4. Compounds having .gamma.-turns and .beta.-turns can be synthesized, regardless of the kinds of amino acid residues, and it is possible to synthesize compounds in which desired amino acid residues are introduced into sites of .beta.-turn and .gamma.-turn based on their importance from the viewpoint of biological activity. The present invention is therefore available for design of compounds having biological activity.

Claims4

Dependent claims

A method of inhibiting binding activity of NK.sub.2 receptors which comprises administering to mammals an effective NK.sub.2 binding inhibiting amount of a cyclic pentapeptide having a .gamma.-turn and a .beta.-turn wherein the cyclic pentapeptide has the following formula (I):

Cyclo (-A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -A.sub.5 -)
wherein A.sub.1 is D-glutamic acid or D-aspartic acid;
A.sub.2 is L-alanine, L-benzylserine, L-benzylthreonine or L-tryptophane;
A.sub.3 is D-leucine;
A.sub.4 is L-leucine;
A.sub.5 is D-tryptophane,
wherein the binding inhibiting activity of said cyclic pentapeptide can be determined by competitive assay with neurokinin A.

4 more elements

Dependencies are inferred from the claim text.

Pentapeptide with specific conformation, its production and use

Life of this patent

Pentapeptide with specific conformation, its production and use

Life of this patent

Abstract

Claims4